The prognostic value of C-reactive protein (CRP) levels in patients with acute ischaemic stroke

Medical Journal of Malaysia

Volumn 59, Issue 5, 2004, Pages 631-637

  Hamidon, Bin Basri ^a   Sapiah, S ^a   Nawawi, H ^a   Raymond, A A ^a  

^a NONE

Author keywords

Acute ischaemic stroke; C reactive protein

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 20544478459     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc. 2000; 75: 369-80.
2. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but non-specific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000; 20: 1047-51.
3. Mattila KJ, Valtonen W, Nieminen MS, Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis. 1998; 26: 719-34.
4. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammmatory cytokines and early neurological worsening in ischaemic stroke. Stroke. 2000; 31: 2325-9.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-9.
6. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischaemic stroke: an independent prognostic factor. Stroke. 2001; 32: 917-24.
7. Muir KW, Weir CJ, Alman W, Squire IB, Lees KR. C-Reactive protein and outcome after Ischaemic stroke. Stroke 1999; 30: 981-5.
8. Di Napoli M, Papa F, Bocola V. Prognostic Influence of Increased C-Reactive protein and Fibrinogen Levels in Ischaemic Stroke. Stroke 2001; 32: 133-8.
9. Bova IY, Bornstein NM, Korezyn AD. Acute infection as a risk factor for ischaemic stroke. Stroke 1996; 27: 2204-6.
10. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta. 1985; 153: 9-13.
11. Tracy RP. Inflammation in cardiovascular disease. Circulation 1998; 97: 2000-2.
12. Tracy RP, Psaty BM, Macy E et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167-76.
13. Kuller LH, Tracy RP. The role of inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2000; 20: 901.
14. Consensus Statement on the Management of Ischaemic stroke. Ministry of Health, Malaysia 2000.
15. Hartmann A, Rundek T, Mast H et al. Mortality and causes of death after first ischaemic stroke. The Northen Manhattan Stroke Study. Neurology 2001; 57: 2000-5.
16. Natalia S.Rost, Philip A.Wolf, Carlos S. Kasesaro et al. Plasma concentration of C-reactive protein and risk of ischaemic stroke and transient ischaemic attack. Stroke 2001; 32: 2575-9.
17. Vemmos KN, Bots ML, Tsibouris PK, et al. Stroke incidence and fatality in Southern Greece: The Arcadia Stroke Registry. Stroke 1999; 30: 363-70.
18. Baranska GM, Ryglewicz D, Lechivicz W, Mendel T, Weissbein T. Risk factors in patients with stroke. Neurology 1993; 27: 625-32.
19. Hung TP. Changes in mortality from cerebrovascular disease and clinical pattern of stroke in Taiwan. J Form Med Ass 1993; 92: 687-96.
20. Jeng JS, Lee TK, Chang YC, et al. Subtype and case fatality rate of stroke; A hospital- based stroke registry in Taiwan. J Neurol Sci 1998; 156: 220-6.
21. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-21.
22. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
23. Sherpherd J, cobble SM, Ford I, et al. Prevention of coronary artery disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7.
24. Sack FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Event trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
25. Michelle A. Albert, ellie Danielson, Nader Rifai, Ridker PM. Effect of statin therapy on C-reactive protein levels. The pravastatin Inflammation / CRP Evaluation (PRINCE): A Randomized trial and Cohort Study. JAMA 2001; 286: 64-70.
26. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid protein in severe unstable angina. N Engl J Med. 1994; 331: 417-24.